The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Four gay men in Africa have HIV. And it’s all Trump’s fault. “Trump aid cuts deal a blow to HIV prevention in Africa,” reads a Reuters byline. The outlet scraped together four interviewees who have ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

And other biotech news brought to you by The Readout.

How an Indian contract manufacturer will establish a biotech foothold in the U.S.

Amy Grant meeting Bono at Charlie Peacock's house in 2002 to discuss the HIV/AIDS crisis. The queen of Christian pop is ...

The visit also served as an opportunity to explore how UNAIDS can support South Africa’s G20 Presidency and the country’s ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The dapivirine ring was originally approved in July 2020 to reduce the risk for HIV-1 infection in women 18 years and older ...